{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:18Z","timestamp":1793747058353,"version":"4.6.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) and solid cancers with liver metastases are indications with high unmet medical need. Interleukin-12 (IL-12) is a proinflammatory cytokine with substantial anti-tumor properties, but its therapeutic potential has not been realized due to severe toxicity. Here, we show that orthotopic liver tumors in mice can be treated by targeting hepatocytes via systemic delivery of adeno-associated virus (AAV) vectors carrying the murine IL-12 gene. Controlled cytokine production was achieved <jats:italic>in vivo<\/jats:italic> by using the tetracycline-inducible K19 riboswitch. AAV-mediated expression of IL-12 led to STAT4 phosphorylation, interferon-\u03b3 (IFN\u03b3) production, infiltration of T cells and, ultimately, tumor regression. By detailed analyses of efficacy and tolerability in healthy and tumor-bearing animals, we could define a safe and efficacious vector dose. As a potential clinical candidate, we characterized vectors carrying the human IL-12 (huIL-12) gene. In mice, bioactive human IL-12 was expressed in a vector dose-dependent manner and could be induced by tetracycline, suggesting tissue-specific AAV vectors with riboswitch-controlled expression of highly potent proinflammatory cytokines as an attractive approach for vector-based cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1360063","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:53:08Z","timestamp":1710492788000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice"],"prefix":"10.3389","volume":"15","author":[{"given":"Matthias J.","family":"D\u00fcchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona F.","family":"Kratzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Vieyra-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sch\u00f6nberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Aljayyoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Martinez","family":"Morilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kreuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Klugmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik H.","family":"Igney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","unstructured":"Cancer Today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacol Therapeut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.109","article-title":"Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12","volume":"8","author":"Hernandez-Alcoceba","year":"2016","journal-title":"Immunotherapy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0019-0","article-title":"Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System\u00ae (RTS\u00ae) gene switch as gene therapy for the treatment of glioma","volume":"25","author":"Barrett","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1452","article-title":"Differential antitumor effect of interleukin-12 family cytokines on orthotopic hepatocellular carcinoma","volume":"12","author":"Lo","year":"2010","journal-title":"J Gene Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.12.5547","article-title":"Tight control of gene expression in mammalian cells by tetracycline-responsive promoters","volume":"89","author":"Gossen","year":"1992","journal-title":"Proc Natl Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.37","article-title":"Development of a liver-specific tet-on inducible system for AAV vectors and its application in the treatment of liver cancer","volume":"19","author":"Vanrell","year":"2011","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.9b00410","article-title":"A small-molecule-responsive riboswitch enables conditional induction of viral vector-mediated gene expression in mice","volume":"9","author":"Strobel","year":"2020","journal-title":"ACS Synth Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1021\/sb500270h","article-title":"Conditional control of mammalian gene expression by tetracycline-dependent hammerhead ribozymes","volume":"4","author":"Beilstein","year":"2015","journal-title":"ACS Synth Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0968-0896(01)00063-3","article-title":"A tetracycline-binding RNA aptamer","volume":"9","author":"Berens","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature02844","article-title":"Exogenous control of mammalian gene expression through modulation of RNA self-cleavage","volume":"431","author":"Yen","year":"2004","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.12.022","article-title":"Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nbt0197-35","article-title":"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo","volume":"15","author":"Lieschke","year":"1997","journal-title":"Nat Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3893","article-title":"Identification of liver-specific enhancer\u2013promoter activity in the 3\u2032 untranslated region of the wild-type AAV2 genome","volume":"49","author":"Logan","year":"2017","journal-title":"Nat Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2019.276","article-title":"A user\u2019s guide to the inverted terminal repeats of adeno-associated virus","volume":"30","author":"Wilmott","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.051","article-title":"Comparative analysis of cesium chloride- and iodixanol-based purification of recombinant adeno-associated viral vectors for preclinical applications","volume":"26","author":"Strobel","year":"2015","journal-title":"Hum Gene Ther Methods"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2002.125","article-title":"IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37\u00b0C. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase","volume":"40","author":"Schumann","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2002.111","article-title":"IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37\u00b0C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase","volume":"40","author":"Schumann","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"B26","first-page":"201","volume-title":"Mikroskopische Technik","author":"Romeis","year":"2015"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1109\/cvpr.2017.243","article-title":"Densely connected convolutional networks","author":"Huang","year":"2017","journal-title":"2017 IEEE Conf Comput Vis Pattern Recognit (CVPR)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0075","article-title":"Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro","volume":"1","author":"Miao","year":"2000","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.11.5864","article-title":"Structure-function analysis of the p35 subunit of mouse interleukin 12 (\u2217)","volume":"270","author":"Zou","year":"1995","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2217","article-title":"Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of cpG depletion of vector genome on CD8+ T cell responses in AAV gene therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.pdf","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of cpG motifs in rAAV genomes: avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9733","DOI":"10.1038\/s41598-021-89124-4","article-title":"Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers","volume":"11","author":"Ahn","year":"2021","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/nejmoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41587-023-01974-7","article-title":"Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration","author":"Greig","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic Malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0472","article-title":"Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","first-page":"clincanres.1512.2018","DOI":"10.1158\/1078-0432.ccr-18-1512","article-title":"First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors","volume":"25","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","author":"Mansurov","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Sci Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.119","article-title":"AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers","volume":"19","author":"Sobrevals","year":"2012","journal-title":"Gene Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"11763","DOI":"10.1038\/s41598-018-29726-7","article-title":"Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD","volume":"8","author":"Reid","year":"2018","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab233","article-title":"Efficient splicing-based RNA regulators for tetracycline-inducible gene expression in human cell culture and C. elegans","volume":"49","author":"Finke","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01989-0","article-title":"Control of mammalian gene expression by modulation of polyA signal cleavage at 5' UTR","author":"Luo","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.016","article-title":"A drug-tunable gene therapy for broad-spectrum protection against retinal degeneration","volume":"26","author":"Santiago","year":"2018","journal-title":"Mol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2174\/1566523216666160524144041","article-title":"Tet-on systems for doxycycline-inducible gene expression","volume":"16","author":"Das","year":"2016","journal-title":"Curr Gene Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/gut.2010.211722","article-title":"Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice","volume":"60","author":"Gonzalez-Aparicio","year":"2011","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.075","article-title":"Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer","volume":"126","author":"Wang","year":"2004","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.012","article-title":"HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system","volume":"10","author":"Ginhoux","year":"2004","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1360063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T08:53:13Z","timestamp":1710492793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1360063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2024.1360063"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1360063","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"1360063"}}